Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Baylor University Medical Center
mi
from
Dallas, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Advanced Liver Therapies at St. Luke's Episcopal Hospital
mi
from
Houston, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Advanced Liver Therapies at St. Luke's Episcopal Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Houston Methodist Hospital
mi
from
Houston, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Houston Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
Houston Methodist
mi
from
Houston, TX
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
Houston Methodist
mi
from
Houston, TX
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
University of California at San Francisco
mi
from
San Francisco, CA
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated:  3/14/2017
NYU Langone Medical Center
mi
from
New York, NY
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients
Status: Enrolling
Updated: 3/14/2017
NYU Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  3/15/2017
Clinical Research Facility
mi
from
New Haven, CT
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 3/15/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated:  3/15/2017
Merck Sharp & Dohme Co. Ltd.
mi
from
Hod Hasharon,
Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)
A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies
Status: Enrolling
Updated: 3/15/2017
Merck Sharp & Dohme Co. Ltd.
mi
from
Hod Hasharon,
Click here to add this to my saved trials
Japanese National Computed Tomographic (CT) Colonography Trial
Evaluation of Accuracy of Computed Tomographic Colonography (CTC) in the Diagnosis of Colorectal Tumors by Gastroenterologists and Radiologists With Computer-aided Detection (CAD): A Multicenter Study
Status: Enrolling
Updated:  3/16/2017
Japanese CTC Society, 3D imaging Laboratory, Massachusetts General Hospital
mi
from
Boston, MA
Japanese National Computed Tomographic (CT) Colonography Trial
Evaluation of Accuracy of Computed Tomographic Colonography (CTC) in the Diagnosis of Colorectal Tumors by Gastroenterologists and Radiologists With Computer-aided Detection (CAD): A Multicenter Study
Status: Enrolling
Updated: 3/16/2017
Japanese CTC Society, 3D imaging Laboratory, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Japanese National Computed Tomographic (CT) Colonography Trial
Evaluation of Accuracy of Computed Tomographic Colonography (CTC) in the Diagnosis of Colorectal Tumors by Gastroenterologists and Radiologists With Computer-aided Detection (CAD): A Multicenter Study
Status: Enrolling
Updated:  3/16/2017
Otarukyokai Hospital
mi
from
Otaru,
Japanese National Computed Tomographic (CT) Colonography Trial
Evaluation of Accuracy of Computed Tomographic Colonography (CTC) in the Diagnosis of Colorectal Tumors by Gastroenterologists and Radiologists With Computer-aided Detection (CAD): A Multicenter Study
Status: Enrolling
Updated: 3/16/2017
Otarukyokai Hospital
mi
from
Otaru,
Click here to add this to my saved trials
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  3/20/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 3/20/2017
Rutgers Cancer Institute of New Jersey at Hamilton
mi
from
Hamilton, NJ
Click here to add this to my saved trials
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  3/20/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Phase II Trial of Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in Patients With HER2/Neu-Overexpressing Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 3/20/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening
Impact of Risk Stratification on Shared Decision-Making for Colorectal Cancer Screening
Status: Enrolling
Updated:  3/20/2017
Boston Med Ctr
mi
from
Boston, MA
Risk Stratification to Promote Effective Shared Decision-Making for Colorectal Cancer Screening
Impact of Risk Stratification on Shared Decision-Making for Colorectal Cancer Screening
Status: Enrolling
Updated: 3/20/2017
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
CyberKnife for Unresectable Renal Tumors
CyberKnife Stereotactic Radiation for Unresectable Renal Tumors/PhaseI Study
Status: Enrolling
Updated:  3/20/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
CyberKnife for Unresectable Renal Tumors
CyberKnife Stereotactic Radiation for Unresectable Renal Tumors/PhaseI Study
Status: Enrolling
Updated: 3/20/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)
Evaluation of Molecular Breast Imaging in Patients With a High Likelihood of Ductal Carcinoma in Situ
Status: Enrolling
Updated:  3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)
Evaluation of Molecular Breast Imaging in Patients With a High Likelihood of Ductal Carcinoma in Situ
Status: Enrolling
Updated: 3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated:  3/21/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated: 3/21/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated:  3/21/2017
Gemelli Hospital Roma / Universita Cattolica del Sacre Cuore Rome
mi
from
Rome,
Radiomics: a Study of Outcome in Lung Cancer
Radiomics: a Prospective Study of Outcome in Lung Cancer
Status: Enrolling
Updated: 3/21/2017
Gemelli Hospital Roma / Universita Cattolica del Sacre Cuore Rome
mi
from
Rome,
Click here to add this to my saved trials
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated:  3/21/2017
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated: 3/21/2017
Holden Comprehensive Cancer Center at University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated:  3/21/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Imaging of Radiolabeled White Blood Cells in Patients With Non-Hodgkin's Lymphoma
In Vivo Imaging of Effector Cells in Anti-Lymphoma Therapy
Status: Enrolling
Updated: 3/21/2017
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy
Status: Enrolling
Updated:  3/21/2017
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy
Status: Enrolling
Updated: 3/21/2017
Lyndon B. Johnson General Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy
Status: Enrolling
Updated:  3/21/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy
Status: Enrolling
Updated: 3/21/2017
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy
Status: Enrolling
Updated:  3/21/2017
Vall d'Hebron Hospital
mi
from
Brussels,
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix
A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy
Status: Enrolling
Updated: 3/21/2017
Vall d'Hebron Hospital
mi
from
Brussels,
Click here to add this to my saved trials
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated:  3/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation
Status: Enrolling
Updated: 3/21/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
Phase I Trial of Intra-tumoral Gemcitabine Therapy for Locally Advanced Pancreatic Carcinoma
Status: Enrolling
Updated:  3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer
Phase I Trial of Intra-tumoral Gemcitabine Therapy for Locally Advanced Pancreatic Carcinoma
Status: Enrolling
Updated: 3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Georegetown University
mi
from
Washington,
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Georegetown University
mi
from
Washington,
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Lakes Research
mi
from
Miami Lakes, FL
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Lakes Research
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
New York Medical College
mi
from
Valhalla, NY
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
St. Francis Hospital
mi
from
Greenville, SC
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
St. Francis Hospital
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Cancer Care Centers of South Texas
mi
from
New Braunfels, TX
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Cancer Care Centers of South Texas
mi
from
New Braunfels, TX
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
Fletcher Allen Health Care and Vermont Cancer Center
mi
from
Burlington, VT
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
Fletcher Allen Health Care and Vermont Cancer Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 3/21/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated:  3/21/2017
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated: 3/21/2017
Moores UC San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated:  3/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated: 3/21/2017
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated:  3/21/2017
Stanford Hospitals and Clinics
mi
from
Stanford, CA
Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery
Status: Enrolling
Updated: 3/21/2017
Stanford Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Univ Of Al At Birmingham
mi
from
Birmingham, AL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Univ Of Al At Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Illinois Cancercare, Pc
mi
from
Peoria, IL
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Illinois Cancercare, Pc
mi
from
Peoria, IL
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Oncology Care Associates, P.A.
mi
from
Wheaton, MD
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Oncology Care Associates, P.A.
mi
from
Wheaton, MD
Click here to add this to my saved trials
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated:  3/22/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors
Status: Enrolling
Updated: 3/22/2017
Masonic Cancer Center at University of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials